How do MedTech investors typically justify a pre-money valuation given long development timelines?

Because MedTech companies frequently lack near-term revenue to support traditional valuation multiples, investors typically triangulate pre-money valuation from comparable private financings at similar development stages, comparable M&A transaction multiples on revenue or installed base for more mature companies, and risk-adjusted net present value models that discount the lead program's potential based on the probability of technical and regulatory success at each remaining milestone. A company approaching a major inflection point, such as a pivotal trial readout or an FDA decision, will typically command a materially different valuation on either side of that event, which is why timing a raise around de-risking milestones matters.

What is the difference between pre-money and post-money valuation, and why does it matter for negotiation?

Pre-money valuation is the company's agreed value before new investment is added, while post-money valuation equals pre-money plus the amount actually being raised in the round; investors and founders sometimes talk past each other because a headline number can be quoted either way, and confirming which figure is being discussed changes the effective price per share and resulting dilution substantially. A round described as 'a $20M raise at a $60M valuation' is ambiguous unless it specifies whether that $60M is pre- or post-money, since the difference changes investor ownership by several percentage points.

What mistake do founders commonly make about pre-money valuation and option pools?

Founders frequently overlook that when an investor requires a larger post-financing option pool as part of the deal, that pool expansion is typically carved out of the pre-money valuation, meaning the dilution from the larger pool falls entirely on existing shareholders rather than being shared with the new investor. Negotiating the option pool size based on an actual, realistic hiring plan rather than accepting a standard 15 to 20 percent pool by default is one of the most effective ways founders can protect pre-money ownership.

All terms

Investment & FinanceStartup Lifecycle

Pre-Money Valuation

Company valuation immediately before new money is invested.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Pre-money valuation is the agreed equity value of a company before a new financing closes. Post-money valuation equals pre-money plus the new investment. The price per share in the round equals pre-money divided by fully-diluted shares outstanding (including option pool top-ups). Investors often require the option pool to be expanded before the round, which lowers the effective pre-money valuation for existing holders. Converting SAFEs and notes also affect the share count used to set the price. Comparing offers on price per share and fully diluted ownership is more accurate than comparing headline valuations.

What the regulation says

Pre-money valuation is a negotiated financing concept, not a value prescribed by MedTech product regulation. In the United States, the relevant legal framework concerns securities offerings and investor protection. Section 17(a) of the Securities Act of 1933, enacted May 27, 1933, prohibits fraud in securities offers and sales, including material misstatements and misleading omissions. It does not prescribe a pre-money formula or guarantee that an agreed valuation is fair. Valuation-related communications should therefore accurately explain material assumptions, including the fully diluted capitalization, option pool expansion, and treatment of converting SAFEs or notes. The SEC regulates how financing interests are offered rather than approving their negotiated price. Regulation D, Rule 506(c), codified at 17 CFR 230.506(c), was adopted by the SEC on July 10, 2013, and became effective September 23, 2013. It permits general solicitation if all purchasers are accredited investors and the issuer takes reasonable steps to verify that status, subject to other applicable conditions. This exemption does not remove antifraud obligations. For MedTech financings, regulatory clearance status, clinical evidence, and reimbursement assumptions may be material to investment decisions, but securities law does not translate them into a mandated valuation.

What this means in practice

Pre-money pricing is the central negotiation in any priced round. In MedTech, comparable companies, comparable transactions (M&A multiples on revenue or enterprise value per installed base), and risk-adjusted NPV of the lead program drive the discussion.

Examples

A MedTech startup developing a novel diagnostic device seeks $5 million in Series A funding. With a pre-money valuation of $20 million, the investors would own 20% of the company after the investment.
During negotiation, investors request that the existing 10% option pool be topped up to 15% before the deal closes. This adjustment effectively dilutes existing shareholders and lowers the effective pre-money valuation for their shares.
A company's pre-money valuation for its seed round was $3 million. When converting SAFEs that totaled $500,000 into equity, the share count used to calculate the new share price was adjusted based on the SAFE terms, impacting the final ownership percentages for all parties.

Common pitfalls

•Forgetting that an option pool 'top-up' typically comes out of pre-money, diluting founders not investors.

Frequently asked questions

Price per share in a priced round equals the pre-money valuation divided by the company's fully diluted share count immediately before the round, which must include all outstanding shares, vested and unvested options, warrants, and any newly created or expanded option pool required by the investor as a condition of the deal. Because the option pool top-up is included in this pre-money share count, increasing the pool size effectively lowers the price per share for the same pre-money valuation, transferring dilution from investors to existing founders and employees rather than the incoming investor.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Investment & Finance

Employee Option Pool

Shares reserved for issuance to employees as stock options.

Investment & Finance

Post-Money Valuation

Company valuation immediately after a financing closes.

Investment & Finance

Term Sheet

Non-binding outline of the key economic and control terms of an investment.

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 4Trade press and expert commentary· 3

Link health: 3 verified· last checked 2026-06-20

PitchBook·1NVCA·1SVB·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Investment & Finance0 / 47

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Investment & Finance
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Company valuation immediately before new money is invested.

·Pre-money pricing is the central negotiation in any priced round.
·In MedTech, comparable companies, comparable transactions (M&A multiples on revenue or enterprise value per installed base), and risk-adjusted NPV of the lead program drive the discussion.
·Post-money valuation equals pre-money plus the new investment.

Remember this

Watch out: Forgetting that an option pool 'top-up' typically comes out of pre-money, diluting founders not investors.

Related terms

You may also need

Auto-suggested from Investment & Finance and shared keywords.

All Investment & Finance terms

Definition

What this means in practice

Examples

Frequently asked questions

Related terms

Editor's picks

More in Investment & Finance

Latest in MedTech

Sources